FUND+ PEOPLE INVESTMENT STRATEGY PORTFOLIO YOUR PROJECT NEWS CONTACT US OUR TEAM More about us OUR TEAM MEMBERS Chris Buyse Managing Partner Chris Buyse was CFO at ThromboGenics NV from September 2006 until June 2014. He has 30 years of experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign. Before this, he was Finance Director of WorldCom/MCI Belux, and was CFO and interim CEO of Keyware Technologies, in addition, he held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent Board Member of a few companies, mostly active in life sciences such as Celyad, Iteos and Bioxodes. Philippe Monteyne Partner Philippe Monteyne holds an M.D. degree trained as a Neurologist and a Ph.D. in Viral Immunology, both at the UCL (Univ. Cathol. de Louvain), followed by a post-doctoral fellowship at Pasteur Institute, Paris. During the last 20 years, he held senior positions in top pharma companies such as SmithKline Beecham, GSK Biologicals (as Head of Global Vaccine Development) and GSK Rare Diseases (Head of Development and Chief Medical Officer) and SANOFI (Vice President R&D France). He is also currently member of different Strategic Advisory Committees. He is also visiting Professor of Neurology at the UCL. Jan Van den Bossche Partner Jan Van den Bossche holds a Master Degree in Applied Economic Sciences at the KU Leuven. He worked for more than 12 years as a biotech analyst at Petercam. He was involved in numerous public and private transactions of Belgian and Dutch Biotech companies, such as ThromboGenics, Tigenix, UCB, AMT (Uniqure), IBA, MDxHealth . Before he joined Fund+, he was for more than 2 years part of the investor relations team at the Dutch life sciences and materials sciences company DSM (Geleen, NL). Alexandra Tolia Partner Alexandra Tolia holds a Ph.D. in Medical Sciences from the KU Leuven, followed by a postdoctoral fellowship at UCSF, and an executive degree in General Management from the Solvay Brussels School of Economics and Management. Before joining Fund+, Alexandra led investments in private and public companies at PMV and Hunza Ventures, where she built strong Life sciences portfolios in Europe and the US. Alexandra is the author of high impact publications in the fields of neurodegeneration and cardiovascular disease and has served as board member in several companies active in biotech, diagnostics and medical technologies. Louis Declerck Associate Louis Declerck is an MD and Biomedical Engineer, trained at the KU Leuven and Ghent University with a specific interest in Biotechnology & Bio-electronics, Neuro-engineering and emerging Medical devices. After one year of co-residency in Neurosurgery, Louis decided to start Biomedical Engineering at Ghent University to explore and contribute to new businesses in the Biomedical and Biotechnology industry. Louis joined Fund+ as Investment Analyst shortly after a one year fellowship in Fund+ during his graduation year. Recently, Louis has been appointed as Associate. Caroline Goddeeris Principal Caroline holds a Ph.D. in Pharmaceutical Sciences at KU Leuven followed by an MBA and an executive master in corporate finance, both from Vlerick Business School. She started her career at UCB taking on various roles ranging from commercial responsibilities (marketing and sales) to business development, portfolio management and R&D strategy. Fascinated by the intersection of research and commercialisation, she then joined Gimv where she focused on early stage biotech and medtech investment opportunities while driving portfolio value as a board member of companies in biotech (Complix) and diagnostics (Multiplicom). Lawrence Van Helleputte Analyst Lawrence holds a PhD in Biomedical Sciences from the VIB-KU Leuven Centre of Brain & Disease Research. There, he focused on the pathophysiology underlying peripheral neuropathies which contributed to the successful creation of Augustine Therapeutics, a spin-off intended to give clinical answers to devastating neuromuscular and neurodegenerative disorders. After his academic passage, Lawrence made the transition to start-up biotech and worked for more than 3 years as a Senior Scientist at CoBioRes NV, converging the preclinical development of targeted anti-cancer therapies. His tremendous desire to work on the frontline of upcoming technologies and innovations directed him towards Fund+, where he recently joined as Scientific Investment Analyst. Diane De Wyngaert Administrative Assistant Diane holds a bachelor degree in informatics. She worked as administrative assistant and bookkeeper for several companies such as ADB (Siemens), VIB and Life Sciences Research Partners (still currently). Contact us Address: Groot Begijnhof 60 3000 Leuven Belgium Phone: +32 (0)16 90 50 00 Email: info@fundplus.be Recent Articles ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors Confo Therapeutics Enters Collaborative Agreement with Regeneron Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis © 2019 FUND+- ALL RIGHTS RESERVED. | We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPTRead More